Beyond TGFβ - Novel ways to target airway and parenchymal fibrosis

被引：15

作者：

Boorsma, C. E. ^{[1
,2
]}

Dekkers, B. G. J. ^{[2
,3
]}

van Dijk, E. M. ^{[2
,4
]}

Kumawat, K. ^{[2
,4
]}

Richardson, J. ^{[5
]}

Burgess, J. K. ^{[6
,7
]}

John, A. E. ^{[8
]}

机构：

[1] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands

[2] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[4] Univ Groningen, Dept Mol Pharmacol, Groningen, Netherlands

[5] Univ Nottingham Hosp, Div Resp Med, Nottingham NG7 2UH, England

[6] Woolcock Inst Med Res, Glebe, NSW 2037, Australia

[7] Univ Sydney, Discipline Pharmacol, Sydney, NSW 2006, Australia

[8] Univ Nottingham Hosp, Div Resp Med, Nottingham NG5 1PB, England

来源：

PULMONARY PHARMACOLOGY & THERAPEUTICS | 2014年 / 29卷 / 02期

基金：

英国医学研究理事会;

关键词：

Fibrosis; Airway; Parenchyma; IPF; COPD; Asthma; IDIOPATHIC PULMONARY-FIBROSIS; TISSUE GROWTH-FACTOR; HUMAN LUNG FIBROBLASTS; WNT1-INDUCIBLE SIGNALING PROTEIN-1; EXTRACELLULAR-MATRIX PRODUCTION; PROTEASE-ACTIVATED RECEPTOR-1; SMOOTH-MUSCLE PHENOTYPE; ANGIOTENSIN-II; SPHINGOSINE; 1-PHOSPHATE; ALVEOLAR MACROPHAGES;

D O I：

10.1016/j.pupt.2014.08.009

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Within the lungs, fibrosis can affect both the parenchyma and the airways. Fibrosis is a hallmark pathological change in the parenchyma in patients with idiopathic pulmonary fibrosis (IPF), whilst in asthma or chronic obstructive pulmonary disease (COPD) fibrosis is a component of the remodelling of the airways. In the past decade, significant advances have been made in understanding the disease behaviour and pathogenesis of parenchymal and airway fibrosis and as a result a variety of novel therapeutic targets for slowing or preventing progression of these fibrotic changes have been identified. This review highlights a number of these targets and discusses the potential for treating parenchymal or airway fibrosis through these mediators/pathways in the future. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：166 / 180

页数：15

共 261 条

[1]

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis [J].